Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-25-051)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (RFA-MH-26-120)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) (RFA-NS-25-017)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Coordinating Center to Support Consortium for Neuroscience AD and ADRD Research in Low- and Middle-Income Countries (U24 Clinical Trial Not Allowed) (RFA-AG-25-014)

Sponsor: National Institute on Aging

Award: Application budgets need to reflect the actual needs of the proposed project and must be limited to $350K in direct costs for year 1, $500k in direct costs for years 2 - 5. The maximum project period is 5 years.

Due Date: Letter of Intent due October 13, 2024. Application due November 13, 2024.

Notice of Special Interest (NOSI): Administrative Supplement Program to Add Fluid-based Biomarkers and APOE Genotyping to NINDS ADRD Human Subjects Research Grants (NOT-NS-24-135)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: Only existing awardees of NINDS AD/ADRD focused grants are eligible to apply. Individual requests can be no more than $150,000 in direct costs. Requests may be for one year of support only and the proposed project period must be within the project period of the parent award.

Due Date: November 11, 2024.

Administrative Supplements to Promote Diversity in Research and Development Small Businesses SBIR/STTR (Admin Supp Clinical Trial Not Allowed) (PA-24-255)

Sponsor: National Institutes of Health, Centers for Disease Control and Prevention

Award: Individual(s) must have support under an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Application budgets are limited to no more than the amount of the current parent award. The project and budget periods must be within the currently approved project period for the existing parent award.

Due Date: Applications are accepted on a rolling basis at any time starting 30 days after the Open Date (varies by IC) until the expiration date (October 14, 2027).

Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed) (RFA-AG-25-032)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $400,000 in direct cost per year. The project period is limited to 5 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

Notice of Intent to Publish an FOA for BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) (NOT-MH-24-365)

Sponsor: National Institutes of Health

Due Date: Estimated Publication Date of Notice of Funding Opportunity: October 14, 2024. First Estimated Application Due Date: June 13, 2025.

NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) (PAR-24-271)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Clinical and Translational Science Award (UM1 Clinical Trial Optional) (PAR-24-272)

Sponsor: National Center for Advancing Translational Sciences

Due Date: Multiple due dates; see announcement.

Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries for Aging and AD and ADRD Research (R03 Clinical Trial Not Allowed) (RFA-AG-25-031)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $100,000 in direct cost per year. The project period is limited to 2 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional) (PAR-24-273)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Administrative Supplement Program to Add Fluid-based Biomarkers and APOE Genotyping to NINDS ADRD Human Subjects Research Grants (NOT-NS-24-109)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: One-year administrative supplement to provide support for currently active NINDS Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) awards to add/include APOE genotype and fluid-based AD/ADRD biomarkers to ongoing AD/ADRD human subjects research studies. Individual requests can be no more than $150,000 in direct costs.

Due Date: November 11, 2024.

ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed) (PAR-24-270)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: November 19, 2024.

Notice of Intent to Publish an FOA for NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)(NOT-AG-24-060)

Sponsor: National Institute on Aging

Due Date: Estimated Publication Date of Notice of Funding Opportunity: November 01, 2024. First Estimated Application Due Date: February 12, 2025.